NCT05487859View on ClinicalTrials.gov

Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Kidney Cancer
Interventions
DRUG

Acarbose Tablets

Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER